However, anti-VEGF monotherapy has limited clinical benefits for cancer patients and in high dosage can often lead to various adverse effects such as hypertension, proteinuria, thromboses, and GIP [27], [28]. This evidence concerns the gene VEGFA and thrombotic disease.